SIETES :: 93010 citas

Resultados de la búsqueda por DISLIPEMIA REFINAR BÚSQUEDA

1.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. [Ref.ID 101586]

2.

Hu Y-m, Zhou F, Yuan Y, Xu Y-c. Efectos del suplemento de probióticos en pacientes con diabetes tipus 2: mataanálisis de ensayos aleatorizados. Med Clin (Barc) 2017;148:362-70. [Ref.ID 101575]

3.

McGettigan P, Ferner RE. PCSK9 inhibitors for hypercholesterolaemia. BMJ 2017;356:j188. [Ref.ID 101397]

4.

Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Unqi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAVOV randomized clinical trial. JAMA 2016;316:2373-84. [Ref.ID 101030]

5.

US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA 2016;316:1997-2007. [Ref.ID 100998]

6.

Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;316:2008-24. [Ref.ID 100989]

7.

Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA 2016;316:1979-81. [Ref.ID 100987]

8.

Greenland P, Bonow RO. Interpretation and use of another statin guideline. JAMA 2016;316:1977-9. [Ref.ID 100986]

9.

Gurwitz JH, Go AS, Fortmann SP. Statins for primary prevention in older adults: uncertainty and the need for more evidence. JAMA 2016;316:1971-2. [Ref.ID 100985]

10.

Thompson PD. What to believe and do about statin-associated adverse efects. JAMA 2016;316:1969-70. [Ref.ID 100984]

11.

Rodríguez F, Harrington RA. Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and the future of LDL-C lowering. JAMA 2016;316:1967-8. [Ref.ID 100983]

12.

Leibowitz M, Karpati T, Cohen-Stavi CJ, Feldman BS, Hoshen M, Bitterman H, Suissa S, Balicer RD. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Intern Med 2016;176:1105-13. [Ref.ID 100700]

13.

Anónimo. Alirocumab. Prescrire 2016;36:331-2. [Ref.ID 100534]

14.

Anónimo. Évolocumab. Prescrire 2016;36:326-31. [Ref.ID 100533]

15.

Warren JB, Dimmitt SB, Stampfer HG. Cholesterol trials and mortality. Br J Clin Pharmacol 2016;82:168-77. [Ref.ID 100478]

16.

Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, for the GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance. The GAUSS-3 randomized clinical trial. JAMA 2016;315:1580-90. [Ref.ID 100239]

17.

Waters DD, Hsue PY, Bangalore S. PCSK9 inhibitors for statin intolerance?. JAMA 2016;315:1571-2. [Ref.ID 100238]

18.

Pintó X, García Gómez MC. Nuevos tratamientos para la hipercolesterolemia. Med Clin (Barc) 2016;146:172-7. [Ref.ID 100102]

19.

Korhonen MJ, Ruokoniemi P, Ilomäki J, Meretoja A, Helin-Salmivaara A, Huupponen R. Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. Pharmacoepidemiol Drug Saf 2016;25:161-9. [Ref.ID 100096]

20.

Anónimo. Two new lipid-regulating drugs. Drug Ther Bull 2016;54:18-21. [Ref.ID 100095]